Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06326931 · ClinicalTrials.gov registry record · Phase 4

Thermal Pulsation Versus Warm Compress Treatment for Meibomian Gland Dysfunction

A Phase 4 study of Meibomian Gland Dysfunction, sponsored by Jacksoneye.

Completed
Registry status
Phase 4
Development phase
68
Enrollment target
1
Study location

NCT06326931 is a Phase 4 study of Meibomian Gland Dysfunction that has completed, run by Jacksoneye. The registered enrollment target is 68 participants, below the 94-participant average among 8 other Meibomian Gland Dysfunction trials with a reported enrollment target (28% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06326931, a Phase 4 study of Meibomian Gland Dysfunction, has completed, sponsored by Jacksoneye.

COMPLETED
Registry status
Phase 4
Development phase
68 participants
Enrollment target
1
Study location

Study Summary

This study aimed to assess the treatment outcome differences between a single, in-office bilateral treatment with the thermal pulsation system and twice-daily, 10-minute applications of the warm compress mask at home for 8 weeks.

Interventions

  • DEVICE thermal pulsation
  • OTHER warm compress

Study Locations (1)

Illinois

  • Jacksoneye - Lake Villa

Trial Details

FieldValue
Enrollment Target 68 participants
Start Date 2022-06-24
Est. Completion 2023-06-22
Phase Phase 4

Sponsor

Jacksoneye

1 total trials

What the Registry Record Tells You About NCT06326931

The ClinicalTrials.gov registry entry for NCT06326931 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 94-participant average among 8 other Meibomian Gland Dysfunction trials with a reported enrollment target (28% lower). The listed sponsor is Jacksoneye, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Meibomian Gland Dysfunction appearing as the primary indexed condition, and to 2 interventions - of which thermal pulsation is the first listed.

NCT06326931 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT06326931 about?

NCT06326931 is a clinical study titled "Thermal Pulsation Versus Warm Compress Treatment for Meibomian Gland Dysfunction". This study aimed to assess the treatment outcome differences between a single, in-office bilateral treatment with the thermal pulsation system and twice-daily, 10-minute applications of the warm compress mask at home for 8 weeks.

What is the current status of trial NCT06326931?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 68 participants. The study started on 2022-06-24. Estimated completion is 2023-06-22.

What conditions does trial NCT06326931 study?

This clinical trial studies the following conditions: Meibomian Gland Dysfunction.

What interventions are being tested in trial NCT06326931?

The interventions under investigation include: thermal pulsation (DEVICE), warm compress (OTHER).

Who is sponsoring clinical trial NCT06326931?

This trial is sponsored by Jacksoneye, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06326931 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Meibomian Gland Dysfunction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.